CVR number 42700649
Industry 46.4620 Wholesale of pharmaceutical goods

NBS Scientific ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 0.0% 0.0% 14.6% 17.4%  
Credit score (0-100)  0 0 0 14 8  
Credit rating  N/A N/A N/A BB B  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Net sales  0 0 0 0 0  
Gross profit  0.0 0.0 0.0 525 535  
EBITDA  0.0 0.0 0.0 -40.8 -38.1  
EBIT  0.0 0.0 0.0 -40.8 -38.1  
Pre-tax profit (PTP)  0.0 0.0 0.0 -40.8 -43.1  
Net earnings  0.0 0.0 0.0 -31.8 -52.1  
Pre-tax profit without non-rec. items  0.0 0.0 0.0 -40.8 -43.1  
 
See the entire income statement

Balance sheet (kDKK) 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 0.0 0.0 8.2 -43.9  
Interest-bearing liabilities  0.0 0.0 0.0 6.4 0.0  
Balance sheet total (assets)  0.0 0.0 0.0 59.1 38.3  
Net Debt  0.0 0.0 0.0 6.4 0.0  
 
See the entire balance sheet

Volume 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 0.0 0.0 525 535  
Gross profit growth  0.0% 0.0% 0.0% 0.0% 1.8%  
Employees  0 0 0 1 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 0 0 59 38  
Balance sheet change%  0.0% 0.0% 0.0% 0.0% -35.2%  
Added value  0.0 0.0 0.0 -40.8 -38.1  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 0.0 0.0 -1.0 -2.0  

Profitability 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 0.0% 0.0% -7.8% -7.1%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 0.0% 0.0% -68.9% -54.0%  
ROI %  0.0% 0.0% 0.0% -278.0% -520.3%  
ROE %  0.0% 0.0% 0.0% -386.9% -223.9%  

Solidity 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Equity ratio %  0.0% 0.0% 0.0% 13.9% -53.4%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% 0.0% -15.8% 0.0%  
Gearing %  0.0% 0.0% 0.0% 78.4% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 155.3%  

Liquidity 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Quick Ratio  0.0 0.0 0.0 1.2 0.5  
Current Ratio  0.0 0.0 0.0 1.2 0.5  
Cash and cash equivalent  0.0 0.0 0.0 0.0 0.0  

Capital use efficiency 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 0.0 0.0 8.2 -43.9  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 -41 -38  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 -41 -38  
EBIT / employee  0 0 0 -41 -38  
Net earnings / employee  0 0 0 -32 -52